Nexanova is a specialist investment firm that selectively funds early stage life science innovations and companies in the U.K., U.S. and Canada, both directly and via venture funds as a limited partner.

​

We focus on early stage innovation on the cusp of preclinical proof-of-concept or validation. We provide seed funding and work actively with inventors, entrepreneurs, and institutions to devise and implement development and commercialization strategies, assemble management teams, and secure additional capital. We aim to leverage the collective experience of our team and global industry network to achieve early exits that generate attractive, risk-mitigated financial returns.

​

Nexanova’s priority is to identify and invest in innovative technologies that will make a real impact on the way diseases are diagnosed and treated. ​Our current focus is on identifying high impact opportunities in the therapeutic, medical device and digital health space, but we are open to ideas across the life science spectrum.